Basic Organization Information
Cancer Research Institute, Inc.
- Also Known As:
-
CRI
- Physical Address:
-
New York, NY
10006
- EIN:
-
13-1837442
- Web URL:
-
www.cancerresearch.org
- NTEE Category:
-
H Medical Research
-
H30 Cancer Research
-
H Medical Research
-
H90 Medical Specialty Research
-
H Medical Research
-
H12 Fund Raising and/or Fund Distribution
- Year Founded:
-
1953
- Ruling Year:
-
1953
Sign in or create an account to see this organization's full address, contact information, and more!
Mission Statement
The Cancer Research Institute (CRI) is learning to harness the power of the immune system to bring new and more effective approaches to cancer treatment, control, and prevention to cancer patients sooner. To accomplish this, CRI funds and coordinates an international network of laboratory and clinical research scientists working within the fields of immunology and tumor immunology. Through integration of basic and clinical research initiatives, CRI is accelerating the discovery, testing, and optimization of next-generation cancer immunotherapies such as cancer vaccines and antibodies.
The Cancer Research Institute identifies top scientific talent through the guidance of the CRI Scientific Advisory Council (SAC), an international roster of leaders in the field of immunology who support CRI's efforts to foster creative, scientifically rigorous research. The SAC counts among its members three Nobel Laureates, 31 members of the National Academy of Sciences, and 24 members of the Academy of Cancer Immunology.
Expert Assessment
There are no Expert Reviews for this organization. Learn more about
TakeAction@GuideStar.
Impact Summary from the Nonprofit
CRI's support of the fields of immunology and tumor immunology has been essential to providing the basic knowledge needed to advance new ideas for immune-based cancer therapies, like cancer vaccines and antibody therapies. Recent FDA approvals of immunotherapies based on the research of CRI scientists include Gardasil (2006), a preventive vaccine for cervical cancer; Provenge (2010), a therapeutic vaccine for prostate cancer; and Yervoy (2011), an antibody to treat advanced melanoma.
Our researchers have made key contributions to our understanding of the immune system, its relationship to cancer, how cancer cancer defends itself against the immune system, and how to stimulate and maintain effective anti-cancer immune responses that destroy or control cancer indefinitely, with minimal harm to a patient's quality of life. In 2011, three Cancer Research Institute-supported immunologists won the Nobel Prize (Beutler, Hoffmann, Steinman) for their contributions to understanding immune system activation. Many more CRI-funded scientists have received top honors and now hold positions of authority within major cancer treatment centers.
Through our Cancer Vaccine Collaborative, a joint program with the Ludwig Institute for Cancer Research, the Cancer Research Institute is spearheading a coordinated, global, academic research effort to learn how best to vaccinate against cancer. In only ten years since its founding, the CVC has conducted nearly 50 clinical trials of different therapeutic vaccine combinations and has produced one of the largest bodies of knowledge on the impact of cancer antigen-specific active immunotherapy.
With these efforts, the Cancer Research Institute is working to bring a new class of cancer treatments--cancer immunotherapy--to patients sooner.
Revenue and Expenses
Sign in or create an account to view this information for the most recent fiscal year.
Revenue and Expense data from Forms 990 for 2011, 2010, 2009, 2008, 2007 are included in the GuideStar Premium Report.
Upgrade Now
Report Added To Cart
Balance Sheet
Balance Sheet data from Forms 990 for Year 2011, 2010, 2009, 2008, 2007 are included in the GuideStar Premium Report.
Upgrade Now
Report Added To Cart
Leadership
Jill O'Donnell-Tormey, Ph.D., Ph.D.
Term:
Since
Feb
1993
Profile:
Dr. Jill O'Donnell-Tormey is a trained cell biologist and immunologist who has been the executive director of the Cancer Research Institute since 1993. During that time, she has been instrumental in increasing the Institute's annual budget twofold. She oversaw the establishment of the Institute's cancer-specific programs, created the International Cancer Immunotherapy Symposia Series, and played a pivotal role in developing the Institute's Clinical Investigation Program, which includes the Cancer Vaccine Collaborative and the Cancer Antigen Discovery Collaborative. She works closely with the Institute's Scientific Advisory Council Director, Lloyd J. Old, M.D., and the Board of Trustees to chart the Institute's strategic course. Prior to her role as Executive Director, Dr. O'Donnell-Tormey served as the Institute's Director of Scientific Affairs from 1987-1993. In that capacity, she greatly increased the Institute's public information program, resulting in the publication of the informative "CRI HelpBook: What To Do If Cancer Strikes" and the highly regarded primer on the field of cancer immunology entitled "Cancer and the Immune System: The Vital Connection," which has recently been updated and is available on the Institute's web site. Dr. O'Donnell-Tormey holds a Bachelor of Science Degree in Chemistry from Farleigh Dickenson University and a Doctor of Philosophy in Cell Biology from The State University of New York's Downstate Medical Center.
Leadership Statement:
Cancer is a disease that affects everyone. While there have been strides in chemotherapy, radiation therapy, and surgical treatments of the disease, cancer continues to claim the lives of millions of people each year. There is a clear and urgent need to develop new approaches to cancer treatment and prevention. The Cancer Research Institute is dedicated to finding novel ways to harness the power of our own immune systems to conquer cancer.
Our work has already made an impact in the lives of people combating cancer. Our Web site (http://www.cancerresearch.org(http://www.cancerresearch.org) ) contains inspirational stories of cancer patients who have participated in early clinical studies of new immunotherapies and who are benefiting from the tremendous strides we are making. You will also read about some of our most talented scientists, whose discoveries are shaping the future of cancer treatment.
I encourage you to take time to browse the site and find out what makes us such a unique and vital force in the search for new and better ways to treat, control, and prevent cancer. Perhaps you may be interested in reading our educational publications, learning about exciting scientific breakthroughs funded by CRI, discovering the rich and vibrant history of the organization(/AboutUs.aspx?id=206) , or finding out how to become involved in one of our special events(/Events.aspx?id=38) . You may even decide that you, too, would like to become part of this important effort by making a donation to support our work.
Thank you for your interest in the Cancer Research Institute. We hope that you will join us as we work together to usher in a new era of cancer therapy.
Highest Paid Employees & Their Compensation
Highest Paid Employee Data for 2011, 2010, 2009, 2008, 2007 are included in the GuideStar Premium Report.
Upgrade Now
Report Added To Cart
Program:
Research Funding
- Budget:
-
$12,201,396
- Category:
-
Medical Research
- Population Served:
-
General Public/Unspecified
Program Description:
CRI's research programs are designed to recognize and support those researchers around the world who are focused on clarifying the link between the immune system and cancer; and on developing immunological approaches to controlling the disease. CRI provides funding at every level of inquiry from the most basic studies to clinical trials testing novel immunotherapies, while at the same time supporting scientists at every career level. The Institute's funding programs include: predoctoral training grants (Predoctoral Emphasis Pathways in Tumor Immunology), postdoctoral fellowships (Irvington Institute Fellowship Program), investigator awards, and a clinical investigation program that supports both translational and preclinical research and clinical trials through its Coordinated Cancer Initiatives (CCI) and the Cancer Vaccine Collaborative (CVC). The core of the CCI lies in bringing together experts from various yet complementary backgrounds who cooperatively design a plan of coordinated research tasks. The Institute then awards short-term funding to individual researchers charged with specific tasks to be accomplished within a specified timeframe. The participating scientists collaborate and communicate, share reagents, data, and ideas, and meet on a regular basis to present their findings and chart the course for the next six to twelve months. The CVC was created in partnership with the Ludwig Institute for Cancer Research, and is a unique network of coordinated early-phase cancer vaccine trials at academic institutions around the world. In addition to its highly competitive research programs, the Institute's educational efforts include sponsoring an annual international symposium that focuses attention on cancer vaccines and antibody-based therapies, the two central approaches of cancer immunology. The Institute also disseminates important information about cancer immunology and immunotherapies to the general public. Finally, each year CRI presents awards to distinguished scientists and dedicated laypersons that have made outstanding contributions to the field of cancer immunology.
Program Long-Term Success:
Program Short-Term Success:
Program Success Monitored by:
Program Success Examples:
Evidence of Impact
Expert Comments
There are no comments available for this organization.
Organizational Strengths
Expert Comments
There are no comments available for this organization.
Areas for Improvement
Expert Comments
There are no comments available for this organization.